product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-Gab1 (Tyr627) (C32H2) Rabbit mAb
catalog :
3233
clonality :
monoclonal
host :
rabbit
conjugate :
nonconjugated
antigen modification :
phosphorylated
clone name :
C32H2
reactivity :
human, mouse, rat
application :
western blot
more info or order :
Cell Signaling Technology product webpage
citations: 8
Published Application/Species/Sample/DilutionReference
  • western blot; human; loading ...; fig 4a
Baumann C, Ullrich A, Torka R. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. Mol Oncol. 2017;11:1430-1447 pubmed publisher
  • western blot; mouse; 1:500; fig 7e
Cai W, Sakaguchi M, Kleinridders A, Gonzalez Del Pino G, Dreyfuss J, O Neill B, et al. Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat Commun. 2017;8:14892 pubmed publisher
  • western blot; human; 1:500; loading ...; fig 4d
Gu Y, Li H, Zhao L, Zhao S, He W, Rui L, et al. GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma. Oncotarget. 2015;6:33658-74 pubmed publisher
Yan S, Um S, Peek V, Stephens J, Zeng W, Konicek B, et al. MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping. Invest New Drugs. 2018;36:536-544 pubmed publisher
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012;11:2149-57 pubmed publisher
Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev I, et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 2012;181:1034-43 pubmed publisher
Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, et al. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012;18:3592-602 pubmed publisher
Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res. 2012;18:1663-71 pubmed publisher
product information
SKU :
3233S
Product-Name :
Phospho-Gab1 (Tyr627) (C32H2) Rabbit mAb
Size :
100 ul
Price-(USD) :
274 USD
Species-x-Reactivity :
H, (M, R)
Applications :
Western blot
Product-Category :
PI3K / Akt Signaling
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
110
Host :
Rabbit
Target :
Gab1 (Tyr627) phosphate
Primary-Protein :
Gab1
Alt-Names :
GAB1,GRB2-associated binder 1,GRB2-associated binding protein 1,GRB2-associated-binding protein 1,Growth factor receptor bound protein 2-associated protein 1
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.